CAR-T cell therapy in Türkiye · for international patients
Advanced CAR-T therapy, coordinated end to end.
CD19/CD22 dual-target and BCMA treatment programmes — manufactured locally with TÜSEB support, delivered in accredited centres, and followed through 30 days of monitoring and beyond, in your own country.
1997
founded · nearly three decades
7–12
days manufacturing
81
provinces covered by our care network
1M+
home-care network visits delivered
Start here
Three readers, three different questions.
A physician, a family and an agency are not looking for the same thing. Choose your path.
What we treat
Lymphoma, leukemia and multiple myeloma.
Our CAR-T therapy programmes target CD19/CD22 dual-target and BCMA — the three targets that cover the disease groups where CAR-T has changed the standard of care.
B-cell lymphoma
Diffuse large B-cell lymphoma and other B-cell non-Hodgkin lymphomas — the largest group of patients treated with CD19-directed CAR-T therapy worldwide.
B-cell acute lymphoblastic leukemia
B-ALL, including relapsed or refractory disease in adults — addressed by CD19- and CD22-directed programmes.
Multiple myeloma
Relapsed or refractory myeloma after prior lines of therapy — addressed by BCMA-directed CAR-T.
Whether CAR-T is suitable for a specific patient is decided only through the eligibility review. This page is informational and is not medical advice.
Start here
Four readers, four different questions.
A physician, a family, an agency and an institution are not asking the same thing. Choose your path.
For patients and families
You are probably reading this at a fragile moment. We cannot tell you the outcome — no honest person can. What we can tell you is what happens, how long it takes, and who stays with you.
- Roughly six weeks in total, with 30 days of close monitoring
- A single coordinator who speaks your language, from start to finish
- What is included and what is not — a clear, written list
For referring physicians
You are the decision-maker for your patient. We give you what you need to stand behind a referral professionally.
- Eligibility criteria and patient selection
- Product information, target antigen and manufacturing chain
- CRS and ICANS grading and management protocols
For agencies and intermediaries
You are the channel, not the brand. We give you the scope, the rules and the terms so the referral works cleanly.
- Service scope and limits — a clear list
- Approved language set and prohibited phrases
- Authorised intermediary requirement and document obligations
For institutions and payers
You are paying a fixed sum. You are entitled to know exactly what it covers and where the surprises cannot come from.
- Fixed package price and what is included
- Hospital responsibility versus what we cover
- Complication insurance, reporting and payment terms
The part others do not describe
The journey does not end at discharge.
Most international CAR-T programmes stop describing the process at the infusion. Very few can describe what happens next — and that is exactly where the difference is made.
Step 1
Eligibility
File and council review
Step 2
Leukapheresis
Cell collection
7–12 days
Manufacturing
CAR-T cells produced
Step 4
Conditioning
Lymphodepletion
Day 0
Infusion
Cells infused back
Step 6
30-day monitoring
Close to centre · CRS and ICANS window
Step 7
Return + follow-up
Remote monitoring in your country
Most programmes end here
Steps six and seven are where the difference is made.
Our licensed home-care network carries the follow-up after discharge — the step that makes the last mile possible.
How long
Approximately six weeks in Türkiye. Thirty of those days require staying close to the treatment centre.
Who is with you
A coordinator who speaks your language, from first contact to the follow-up after you return home.
Back home
Follow-up continues through our licensed home-care network, coordinated with your own physician.
81
provinces
300+
nurses
95+
physicians
Verifiable
What you can check yourself.
Trust in international healthcare is not built with adjectives. Everything below can be independently verified. We will give you the references to do it.
International Health Tourism Authorisation Certificate
Registered with the Ministry of Health, listed on HealthTürkiye.
Licensed CD19/CD22 dual-target and BCMA CAR-T products
Validated manufacturing to TİTCK and EMA standards, 4+ treatment types available.
GMP CAR-T production in Ankara
A certified GMP production centre established with TÜSEB support — 10+ treatment centres in our network, with an active clinical study running in three centres.
Ministry-licensed home healthcare
The network that carries the follow-up — 81 provinces — bringing CAR-T follow-up to every corner of Türkiye, 300+ nurses, 95+ physicians, 1M+ visits.
Omega Genetics Laboratory
Our own genetic diseases evaluation centre supports the programme with laboratory testing before and during treatment. Licensed by the Ministry of Health and authorized for international health tourism.
Health Tourism Authorisation Certificate
2026006015610080000497154 · 2026-06-05
Ask for a review, not a commitment.
We reply within one working day, in your language. If this is not the right route for you, we will say so, clearly and without pressure.
The information on this site is for general informational purposes only. CAR-T cell therapy eligibility is determined solely through specialist physician evaluation. This site does not constitute medical advice.